Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

Atrial High Rate Episodes Clinical Trial

— NOAH  

Official title:

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02618577
• Other study ID #: NOAH - AFNET 6
• Secondary ID: 2015-003997-33
• Status: Terminated
• Phase: Phase 3
• Start date: February 2016
• Est. completion date: December 31, 2022

Study information

• Verified date: July 2023
• Source: Atrial Fibrillation Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be conducted in several European countries.

Description:

Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documented by conventional ECG recordings. It is well established that a large proportion of AF episodes remain undiagnosed ("silent AF"), and many of these patients present with a stroke as the first clinical sign of AF. Earlier initiation of anticoagulation could prevent such events. Continuous monitoring of atrial rhythm by implanted devices could close this diagnostic gap. Pacemakers, defibrillators, and cardiac resynchronisation devices already provide automated algorithms alerting to the occurrence of highly organised atrial tachyarrhythmia episodes, also called "subclinical atrial fibrillation" or, more commonly, "atrial high rate episodes" (AHRE). Data from large prospectively followed patient cohorts demonstrated that stroke rate is increased in patients with AHRE. A sizeable portion of these patients develops clinically detected AF over time. In these patients, AHRE can be considered as an early manifestation of paroxysmal AF. A few AHRE patients do not develop clinically overt AF, and the absolute stroke rates are lower in patients with AHRE when compared to stroke rates in patients with clinically diagnosed AF. In light of the bleeding complications associated with oral anticoagulant therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with AHREs.

The Non-vitamin K antagonist Oral anticoagulants (NOACs) provide similar or slightly better stroke prevention, and appear slightly safer compared to vitamin K antagonists (VKAs). In addition, no individual therapy adjustment of NOACs has to be performed. Edoxaban, a newly introduced NOAC, at a dose regime of 60 mg once daily (OD) has a favourable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial, edoxaban prevented strokes at least as effectively as VKA therapy but caused less major bleeding events than VKA therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2608
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation

• AHRE detection feature activated for adequate detection of AHRE (refer to Appendix XIII)

• AHRE (= 170 bpm atrial rate and = 6 min duration) documented by the implanted device via its atrial lead and stored digitally. Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible

• Provision of signed informed consent

• Age = 65 years

In addition, at least one of the following cardiovascular conditions leading to a modified CHA2DS2VASc score of 2 or more:

• Age = 75 years

• Heart failure (clinically overt or LVEF < 45%)

• Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihyper-tensive therapy or resting blood pressure > 145/90 mmHg)

• Diabetes mellitus

• Prior stroke or transient ischemic attack (TIA)

• Vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram [TEE])

• Provision of signed informed consent

Exclusion Criteria:

• Any disease that limits life expectancy to less than 1 year

• Participation in another controlled clinical trial, either within the past two months or still ongoing

• Previous participation in the present trial NOAH - AFNET 6

• Drug abuse or clinically manifest alcohol abuse

• Any history of overt AF or atrial flutter

• Indication for oral anticoagulation (e.g. deep venous thrombosis)

• Contraindication for oral anticoagulation in general

• Contraindication for edoxaban as stated in the current SmPC

• Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present

• Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation

• End stage renal disease (creatinine clearance (CrCl) < 15 ml/min as calculated by the Cockcroft-Gault method)

• All persons exempt from participation in a clinical trial by law

Related Conditions & MeSH terms

• Atrial High Rate Episodes

Intervention

Drug:
• Edoxaban
Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics: Impaired renal function (CrCl 15-50 ml/min), or low body weight (=60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.
• ASA
ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripherial or coronary artery disease, a prior myocardial infarction, or a prior stroke.

Locations

Country	Name	City	State
Austria	Several Sites	Multiple Locations
Belgium	Several Sites	Multiple Locations
Bulgaria	Several	Multiple Locations
Czechia	Several	Multiple Locations
Denmark	Several	Multiple Locations
France	Several	Multiple Locations
Germany	Several Sites	Multiple Locations
Greece	Several	Multiple Locations
Hungary	Several	Multiple Locations
Italy	Several	Multiple Locations
Netherlands	Several	Multiple Locations
Poland	Several	Multiple Locations
Portugal	Several	Multiple Locations
Romania	Several	Multiple Locations
Spain	Several	Multiple Locations
Sweden	Several	Multiple Locations
Ukraine	Several	Multiple Locations
United Kingdom	Several	Multiple Locations

Sponsors (3)

Lead Sponsor	Collaborator
Atrial Fibrillation Network	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Countries where clinical trial is conducted

Austria,  Belgium,  Bulgaria,  Czechia,  Denmark,  France,  Germany,  Greece,  Hungary,  Italy,  Netherlands,  Poland,  Portugal,  Romania,  Spain,  Sweden,  Ukraine,  United Kingdom, 

References & Publications (2)

Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, de Groot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019 Oct 1;21(10):1459-1467. doi: 10.1093/europace/euz172. — View Citation

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	stroke, systemic embolism, or cardiovascular death	Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death	28 months
Secondary	Components of the primary outcome	All-cause death Major bleeding events according to the ISTH definitions Quality of life changes at 12 and 24 months compared to baseline Patient satisfaction at 12 and 24 months compared to baseline Cost effectiveness and health resource utilisation Patient autonomy changes at 12 and 24 months compared to baseline including chronic consequences of stroke (aphasia, hemianopia ("mild stroke")) Cognitive function at 12 and 24 months compared to baseline	28 months
Secondary	Major Adverse Cardiac Events (MACEs: cardiac death, myocardial infarction, acute coronary syndrome (ACS)	PCI, CABG	28 months
Secondary	All-cause death	All-cause death	28 months
Secondary	Major bleeding events	according to the International Society on Thrombosis and Haemostasis (ISTH) definitions	28 months
Secondary	Quality of life changes at 12 and 24 months compared to baseline	assessed by EQ-5D including its visual-analogue scale and by the Karnofsky scale	28 months
Secondary	Patient satisfaction at 12 and 24 months compared to baseline	assessed by PACT-Q	28 months
Secondary	Cost effectiveness and health resource utilisation	estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies	28 months
Secondary	Changes of autonomy status in patients with stroke during study participation	potentially assessed at each FU visit by modified Rankin scale; a maximum of 2 subsequent assessments in FU per patient with stroke should be performed	28 Months
Secondary	Cognitive function	MoCA test at 12 and 24 months compared to baseline	28 months

External Links

•   NOAH Trial